Germany's medical regulator says it has received reports of 21 cases of rare blood clots in people who had recently received AstraZeneca's coronavirus vaccine.
The Paul Ehrlich Institute said in an email Monday to The Associated Press that seven people affected by the blood clots have died.
The incidence of an unusual form of blood clot in the head, known as sinus vein thrombosis, prompted several European countries to temporarily halt the use of the AstraZeneca vaccine earlier this month. After a review by medical experts. the European Union's medical regulator EMA recommended that warnings about possible rare side effects should be added to the vaccine information provided for patients and doctors.
Most EU countries have since resumed use of the vaccine.
The Paul Ehrlich Institute said that of the 21 cases reported in Germany until March 25, 12 also involved an abnormally low level of platelets in the patients' blood.
Of the 21 cases, 19 were in women ages 20 to 63, while two were in men ages 36 and 57.
During the period covered by the reports, some 2.27 million first doses of the AstraZeneca vaccine were administered in Germany.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU